Octreotid Hexal (Octreotide)

Octreotide mimics natural somatostatin and binds to somatostatin receptors, especially subtypes sst2 and sst5. This binding inhibits adenylate cyclase, reduces cAMP formation, and consequently decreases the secretion of several hormones and peptides, including growth hormone, serotonin, and vasoactive intestinal peptide.

The dosage of Octreotid Hexal is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the specific indication, patient characteristics, and clinical response. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for octreotide in pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Healthcare providers must assess the risk‑benefit profile for each patient before prescribing.

To request Octreotid Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Octreotid Hexal contains octreotide, which shares the same mechanism as other somatostatin analogues like lanreotide. While both suppress hormone secretion, differences may exist in formulation, dosing frequency, and pharmacokinetic profiles. Choice of agent depends on clinical factors, patient preference, and physician judgment.

Octreotid Hexal should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside this range.

Octreotid Hexal is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdominal wall or thigh, following aseptic technique. Administration instructions, including injection site rotation and needle handling, are provided by the prescribing clinician.

Serious risks include severe hypersensitivity reactions (anaphylaxis), pancreatitis, gallbladder disease such as acute cholecystitis, significant hyperglycemia, and cardiac arrhythmias. Patients should be monitored closely for these events, and therapy should be discontinued if any serious adverse reaction occurs.

Octreotid Hexal is contraindicated in patients with known hypersensitivity to octreotide or any excipients in the formulation. Caution is advised for individuals with severe hepatic or renal impairment, uncontrolled diabetes, or active gallbladder disease. A prescriber should evaluate each patient’s medical history before initiating therapy.